Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 282

1.

The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Mease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, Palmer RH.

J Rheumatol. 2009 Feb;36(2):398-409. doi: 10.3899/jrheum.080734. Erratum in: J Rheumatol. 2009 Mar;36(3):661.

PMID:
19132781
2.

Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y.

Clin Ther. 2008 Nov;30(11):1988-2004. doi: 10.1016/j.clinthera.2008.11.009. Erratum in: Clin Ther. 2009 Feb;31(2):446. Clin Ther. 2009 Jul;31(7):1617.

PMID:
19108787
3.

Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y.

Arthritis Rheum. 2010 Sep;62(9):2745-56. doi: 10.1002/art.27559.

4.

A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.

Geisser ME, Palmer RH, Gendreau RM, Wang Y, Clauw DJ.

Pain Pract. 2011 Mar-Apr;11(2):120-31. doi: 10.1111/j.1533-2500.2010.00403.x.

PMID:
20642487
5.

Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.

Goldenberg DL, Clauw DJ, Palmer RH, Mease P, Chen W, Gendreau RM.

Pain Med. 2010 Feb;11(2):180-94. doi: 10.1111/j.1526-4637.2009.00755.x. Epub 2009 Dec 9.

6.

Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.

Branco JC, Cherin P, Montagne A, Bouroubi A; Multinational Coordinator Study Group..

J Rheumatol. 2011 Jul;38(7):1403-12. doi: 10.3899/jrheum.101025. Epub 2011 Apr 1.

PMID:
21459941
7.

Efficacy of milnacipran in patients with fibromyalgia.

Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ.

J Rheumatol. 2005 Oct;32(10):1975-85.

PMID:
16206355
8.

Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran.

Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA.

Pain. 2010 May;149(2):373-8. doi: 10.1016/j.pain.2010.02.043. Epub 2010 Mar 23.

PMID:
20332060
9.

A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.

Branco JC, Zachrisson O, Perrot S, Mainguy Y; Multinational Coordinator Study Group..

J Rheumatol. 2010 Apr;37(4):851-9. doi: 10.3899/jrheum.090884. Epub 2010 Feb 15.

PMID:
20156949
10.

A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.

Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG.

Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S27-35.

PMID:
15378666
11.

Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.

Arnold LM, Palmer RH, Gendreau RM, Chen W.

Psychosomatics. 2012 Jul-Aug;53(4):371-9. doi: 10.1016/j.psym.2012.02.005. Epub 2012 Jun 6.

PMID:
22677218
12.

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.

Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.

Arthritis Rheum. 2004 Sep;50(9):2974-84.

13.

Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.

Arnold LM, Hirsch I, Sanders P, Ellis A, Hughes B.

Arthritis Rheum. 2012 Jul;64(7):2387-97. doi: 10.1002/art.34390.

14.

Milnacipran: in fibromyalgia.

Chwieduk CM, McCormack PL.

Drugs. 2010;70(1):99-108. doi: 10.2165/11202810-000000000-00000.

PMID:
20030428
15.

Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.

Isaac MT, Isaac MB, Gallo F, Tournoux A.

Hum Psychopharmacol. 2003 Dec;18(8):595-601.

PMID:
14696018
16.

Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.

Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, Courvoisier D, Montagne A, Dayer P, Desmeules JA.

Pain Physician. 2013 Sep-Oct;16(5):E553-62.

18.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
19.

Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial.

Gür A, Karakoc M, Nas K, Cevik R, Sarac J, Ataoglu S.

Rheumatol Int. 2002 Sep;22(5):188-93. Epub 2002 Jul 6.

PMID:
12215864
20.

Milnacipran for pain in fibromyalgia in adults.

Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ.

Cochrane Database Syst Rev. 2015 Oct 20;(10):CD008244. doi: 10.1002/14651858.CD008244.pub3. Review.

PMID:
26482422

Supplemental Content

Support Center